Evidence map›Paper›PMID 30030661›Full record

ArticleInternational ophthalmology2019

Visual prognosis, clinical features, and predisposing factors in non-HIV patients with cytomegalovirus retinitis.

Nasser Shoeibi, Majid Abrishami, Erfan Mohammad Esmaeil, Seyedeh Maryam Hosseini

Abstract read
PubMed Publisher
In one paragraph

Article in International ophthalmology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Nasser ShoeibiEye Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Majid AbrishamiEye Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Erfan Mohammad EsmaeilRetina Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Seyedeh Maryam HosseiniEye Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. smaryam_hosseini@yahoo.com.
Mashhad University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo study the characteristics and visual outcome of cytomegalovirus retinitis in patients of a tertiary referral ophthalmology center.

methodsThis retrospective cross-sectional study included 16 patients who presented with CMV retinitis between February 2014 and January 2017. Demographics, clinical signs, course of treatment, and visual and anatomical results were analyzed.

resultsTwenty five eyes of 16 patients were included. Eleven (68.8%) were females. The mean age was 29.37 ± 17.12 (range 11-73) years. Involvement was bilateral in 9 (56.2%) cases. HIV serology was negative in all patients. Best-corrected visual acuity was 0.57 ± 0.55 logarithm of the minimal angle of resolution (LogMAR) at the time of presentation and decreased to 0.69 ± 0.55 LogMAR on final visit (P = 0.332). None of the patients participating in this study was HIV-positive.

conclusionCMV retinitis is a devastating complication in immunosuppressed. The visual acuity usually decreases despite aggressive appropriate treatment. This observation supports the increasing incidence of CMV infection in non-HIV patients.

Indexed as

AdolescentAdultAgedAntiviral AgentsChildCross-Sectional StudiesCytomegalovirus RetinitisEye Infections, ViralFemaleFollow-Up StudiesHIVHIV InfectionsHumansMaleMiddle AgedPrognosisAntiviral AgentsCytomegalovirus retinitisHIVNon-HIVOrgan transplantationVisual prognosis

Identifiers

PMID30030661
OpenAlexW2883879220

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.